Shuttle Pharmaceuticals Holdings (SHPH) Net Income towards Common Stockholders (2021 - 2026)

Shuttle Pharmaceuticals Holdings' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 20.14% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$12.0 million (down 28.06% YoY), while the FY2025 annual figure was -$19.7 million, down 54.97% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$2.5 million, up from -$2.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$623043.0 in Q2 2022, with the low at -$4.4 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$1.9 million (2024), against an average of -$2.2 million.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders tumbled 807.29% in 2022, then surged 62.7% in 2023.
• Shuttle Pharmaceuticals Holdings' Net Income towards Common Stockholders stood at -$4.4 million in 2022, then soared by 62.7% to -$1.6 million in 2023, then soared by 33.81% to -$1.1 million in 2024, then sank by 168.25% to -$2.9 million in 2025, then rose by 13.6% to -$2.5 million in 2026.
• Business Quant data shows SHPH's Net Income towards Common Stockholders at -$2.5 million in Q1 2026, -$2.9 million in Q4 2025, and -$2.4 million in Q3 2025.